The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
Stijn Moens(VIB-KU Leuven Center for Cancer Biology), Frédéric Amant(KU Leuven)
Cited by 27
Related Papers
Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
|The Lancet Oncology|2018|371
In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer
|International Journal of Molecular Sciences|2016|5